Holen Sie sich die Stockscreener-App
4.62
0.65%
0.03
Handel nachbörslich:
4.62
Schlusskurs vom Vortag:
$4.59
Offen:
$4.58
24-Stunden-Volumen:
788.30K
Relative Volume:
0.60
Marktkapitalisierung:
$596.64M
Einnahmen:
$204.17M
Nettoeinkommen (Verlust:
$-74.00M
KGV:
-8.00
EPS:
-0.5775
Netto-Cashflow:
$-12.84M
1W Leistung:
+0.65%
1M Leistung:
+14.07%
6M Leistung:
-15.23%
1J Leistung:
+29.78%
1-Tages-Spanne:
$4.525
$4.68
1-Wochen-Bereich:
$4.31
$4.735
52-Wochen-Spanne:
$3.09
$6.18
Cytek Biosciences Inc Stock (CTKB) Company Profile
Firmenname
Cytek Biosciences Inc
Sektor
Branche
Telefon
(877) 922-9835
Adresse
47215 LAKEVIEW BOULEVARD, FREMONT
Compare CTKB vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTKB
Cytek Biosciences Inc
|
4.62 | 596.64M | 204.17M | -74.00M | -12.84M | -0.5775 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cytek Biosciences Inc Stock (CTKB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-05-09 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-31 | Herabstufung | Goldman | Buy → Sell |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-07-19 | Eingeleitet | Raymond James | Mkt Perform |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
Alle ansehen
Cytek Biosciences Inc Aktie (CTKB) Neueste Nachrichten
BlackRock (NYSE: CTKB) holds 7.2% — 9.36M shares of Cytek Biosciences - Stock Titan
Cytek Biosciences expands flow cytometry footprint amid growing immunology demand - ad-hoc-news.de
CTKBCytek BioSciences Inc Latest SEC Filings - Finviz
If You Invested $1,000 in Cytek Biosciences, Inc. (CTKB) - Stock Titan
Cytek Biosciences explores growth paths as investors weigh long-term potential - ad-hoc-news.de
Cytek Biosciences (CTKB) Edges Higher as Shares Stabilize Near SupportTICK Divergence - dars.gov.et
June 2026 Penny Stocks With Promising Potential - Sahm
Cytek Biosciences (NASDAQ: CTKB) adds Chief Legal Officer as reporting insider - Stock Titan
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from Russell 2000 Defensive Index - marketscreener.com
Enterprise value to revenue forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
Price to earnings forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
Enterprise value to EBIT forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
Price to sales forward of Cytek Biosciences, Inc. – NASDAQ:CTKB - TradingView
Cytek Biosciences, Inc.(NasdaqGS:CTKB) dropped from Russell 2000 Value-Defensive Index - marketscreener.com
Enterprise value to revenue forward of Cytek Biosciences, Inc. – BOATS:CTKB - TradingView
CTKB Forecast — Price Target — Prediction for 2027 - TradingView
8EQ Forecast — Price Target — Prediction for 2027 - TradingView
Cytek Biosciences, Inc. Actuals & Estimates (NASDAQ:CTKB) - TradingView
Cytek Biosciences Announces Chief Legal Officer Transition - The Globe and Mail
Cytek Biosciences, Inc. Actuals & Estimates (GETTEX:8EQ) - TradingView
Cytek Biosciences' Valerie Barnett to Depart as Chief Legal Officer and Corporate Secretary - TradingView
Cytek Biosciences (NASDAQ: CTKB) legal chief exit detailed - Stock Titan
Cytek Biosciences, Inc. Announces Termination of Valerie Barnett as Chief Legal Officer and Corporate Secretary, Effective June 29, 2026 - marketscreener.com
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P 1000 - marketscreener.com
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P 600 Health Care - marketscreener.com
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P Composite 1500 - marketscreener.com
Cytek Biosciences, Inc.(NasdaqGS: CTKB) dropped from S&P 600 - marketscreener.com
Cytek Biosciences Inc (CTKB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cytek Biosciences Stockholders Back Board, Pay and Auditor - The Globe and Mail
Cytek Biosciences (CTKB) Stock Sees Fair Value Falls After Analysts Cut Targets - Yahoo Finance
Cytek Biosciences Inc (CTKB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cytek Biosciences Inc (CTKB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cytek Biosciences Inc (CTKB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cytek Biosciences shareholders elect directors and approve key proposals at annual meeting By Investing.com - Investing.com South Africa
Cytek Biosciences shareholders elect directors and approve key proposals at annual meeting - Investing.com Canada
Cytek Biosciences launches quick reference guide to streamline lab use of cFluor dyes - Traders Union
Cytek Biosciences Inc (CTKB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cytek Biosciences (CTKB) CTO Yan Ming reports bona fide gift of shares - Stock Titan
Cytek Biosciences Inc (CTKB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cytek Biosciences (CTKB) details 2026 shareholder meeting voting outcomes - Stock Titan
Cytek Biosciences Inc (CTKB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cytek Biosciences Inc (CTKB) Institutional Confidence - TradingKey
Cytek Biosciences (CTKB) Singular Research’s Las Vegas Invitational Conference summary - Quartr
Cytek Biosciences, Inc. (CTKB) Presents at Singular Research's Las Vegas Invitational ConferenceSlideshow - Seeking Alpha
Cytek Biosciences (CTKB) director converts 43,973 RSUs to common stock - Stock Titan
[Form 4] Cytek Biosciences, Inc. Insider Trading Activity - Stock Titan
Cytek Biosciences (CTKB) director Glenn Muir files initial ownership report - Stock Titan
Cytek Biosciences (CTKB) director awarded 18,261 options plus 33,333 RSUs - Stock Titan
Cytek Biosciences (CTKB) director boosts stake with RSU exercise and new option, RSU grants - Stock Titan
Cytek Biosciences (CTKB) director exercises RSUs and receives new equity awards - Stock Titan
Cytek Biosciences (CTKB) director exercises 43,973 RSUs, granted options and RSUs - Stock Titan
Finanzdaten der Cytek Biosciences Inc-Aktie (CTKB)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):